RecruitingPhase 2NCT07483554

IBI343 in Combination Therapy for Advanced Malignant Solid Tumors

A Phase II Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of IBI343 in Combination Therapy for Patients With Advanced Malignant Solid Tumors.

Sponsor

Innovent Biologics (Suzhou) Co. Ltd.

Enrollment

389 participants

Start Date

Apr 20, 2026

Study Type

INTERVENTIONAL

Conditions

Pancreatic Ductal Adenocarcinoma Gastric/Gastroesophageal Junction Adenocarcinoma CLDN18.2 Positive

Summary

A Phase II study to evaluate the safety, tolerability, pharmacokinetics, and efficacy of IBI343 in combination therapy for patients with advanced malignant solid tumors.To evaluate the efficacy and safety of IBI343 in combination therapy for patients with advanced malignant solid tumors.Enrollment of subjects with advanced gastric/gastroesophageal junction adenocarcinoma positive for CLDN18.2, and subjects with pancreatic ductal adenocarcinoma positive for CLDN18.2.

Eligibility

Min Age: 18 Years

Plain Language Summary

Simplified for easier understanding

This clinical trial is studying a drug called IBI343,Gemcitabine, Albumin-bound Paclitaxel for people with cldn18.2 positive, gastric/gastroesophageal junction adenocarcinoma, and other related conditions. The study is currently recruiting participants at 1 location. People eligible for this study include aged 18 Years and older.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.